Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
HemaSphere · 2025-01 · 9 (1)
DOI: 10.1002/hem3.70070 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 16.01.2025. Verfasst von Maximilian Merz und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases Universitätsklinikum Leipzig Leipzig Germany. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide‐cel ( n = 162) versus cilta‐cel ( n = 42). Co‐primary efficacy endpoints of the study were overall response rate (ORR) and progression‐free survival (PFS). Co‐primary safety endpoints were the incidence of cytokine release syndrome (CRS) and immune‐effector cell‐associated neurotoxicity syndrome (ICANS). Median turnaround time between apheresis and infusion was 47 days for ide‐cel versus 68 days for cilta‐cel ( p < 0.001). Cilta‐cel showed significantly higher ORR (93% vs. 79%; p < 0.001), with complete response at Day 30 of 48% versus 26% ( p < 0.001). The 10‐month PFS and overall survival (OS) was 82% and 90% for cilta‐cel versus 47% and 77% ide‐cel ( p < 0.001 and p = 0.06), and improved outcome for cilta‐cel was confirmed after multivariable adjustment. Incidence of CRS and ICANS appeared similar (81% and 19% for cilta‐cel versus 85% and 19% for ide‐cel), while 10% and 7% in the cilta‐cel group versus 4% and 2% in the ide‐cel group showed severe CRS and ICANS grade 3–4, with CRS occurring significantly earlier for ide‐cel (median, 2 days vs. 4 days; p < 0.001). Nonrelapse mortality was 5% for cilta‐cel versus 3% for ide‐cel ( p = 0.51). Cilta‐cel showed later peak of CAR‐T expansion at Day 14 versus Day 7 for ide‐cel, while cilta‐cel expansion was associated with ICANS. Our study provides real‐world evidence that cilta‐cel was associated with superior outcomes and distinct cellular dynamics versus ide‐cel in triple‐class exposed RRMM.
Autor:innen und Institutionen
- Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases Universitätsklinikum Leipzig Leipzig Germany.
- Klinik für Innere Medizin II - Hämatologie, Onkologie, University Hospital Schleswig-Holstein Kiel Kiel University Kiel Germany.
- Department of Haematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen University of Duisburg-Essen Essen Germany.
- Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation University Medical Center Hamburg-Eppendorf Hamburg Germany.
- Klinik für Hämatologie, Onkologie und Klinische Immunologie, Heinrich Heine University University Hospital Düsseldorf Düsseldorf Germany.
- Medizinische Klinik und Poliklinik III - Innere Medizin mit den Schwerpunkten Onkologie, Hämatologie, Immunonkologie und Rheumatologie Universitätsklinikum Bonn Bonn Germany.
ORCID-Profile: Maximilian Merz, Fabian Müller, Vladan Vucinic, Christine Hanoun, Carlos Fernández de Larrea, Nico Gagelmann
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Merz, M., Albici, A. M., von Tresckow, B., Rathje, K., Fenk, R., Holderried, T., Müller, F., Tovar, N., Oliver-Cáldes, A., Vucinic, V., Kharboutli, S., Bärmann, B. N., Ayuk, F., Platzbecker, U., Stölzel, F., Schub, N., Schmitz, F., Fandrei, D., Born, P., …, & Gagelmann, N. (2025). Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. HemaSphere, 9(1). https://doi.org/10.1002/hem3.70070
Vancouver
Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. HemaSphere. 2025;9(1). doi:10.1002/hem3.70070
BibTeX
@article{Merz2025,
author = {Merz, Maximilian and Albici, Anca-Maria and von Tresckow, Bastian and Rathje, Kristin and Fenk, Roland and Holderried, Tobias and Müller, Fabian and Tovar, Natalia and Oliver-Cáldes, Aina and Vucinic, Vladan and Kharboutli, Soraya and Bärmann, Ben-Niklas and Ayuk, Francis and Platzbecker, Uwe and Stölzel, Friedrich and Schub, Nathalie and Schmitz, Friederike and Fandrei, David and Born, Patrick and Khandanpour, Cyrus and Hanoun, Christine and Hörster, Keven and Teichert, Marcel and Jeker, Barbara and Hoffmann, Michele and Kröger, Nicolaus and de Larrea, Carlos Fernández and Pabst, Thomas and Gagelmann, Nico},
title = {Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {1},
doi = {10.1002/hem3.70070}
}
EUVIMED